MedTrace Logo

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

NCT00133874 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2017-01-23

No results posted yet for this study

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

Conditions

  • Skin Infections, Bacterial

Interventions

DRUG

SB-275833 ointment, 1%

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-09-30
Completion
2005-09-30

Countries

  • Canada
  • Costa Rica
  • France
  • Germany
  • India
  • Mexico
  • Netherlands
  • Peru
  • Poland
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133874 on ClinicalTrials.gov